Test Catalog

Test Id : MUMPU

Order This Test

Mumps Virus, Molecular Detection, PCR, Urine

Download
Overview

Test Catalog

Useful For
Suggests clinical disorders or settings where the test may be helpful

Method Name
A short description of the method used to perform the test

Real-Time Polymerase Chain Reaction (PCR)

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Mumps Virus PCR, Urine

Aliases
Lists additional common names for a test, as an aid in searching

MUMPU

Mumps virus

Mumps

Specimen Type
Describes the specimen type validated for testing

Urine

Ordering Guidance

Polymerase chain reaction testing (this test) is recommended as the first-line test if a patient has symptoms of mumps (ie, fever, swollen salivary/parotid glands).

 

If serology has been performed and IgM-class antibodies against mumps are detected (MMPGM / Mumps Virus Antibody, IgM and IgG, Serum), this test should be ordered to confirm mumps infection.

Shipping Instructions

Specimens must be shipped at refrigerated temperature. Specimens received frozen will be rejected.

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Supplies: Urine Tubes, 10 mL (T068)

Container/Tube: Plastic, 10-mL urine tube

Specimen Volume: 1 mL

Collection Instructions:

1. Collect a random urine specimen.

2. No preservative.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.

0.3 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Samples that have been heat-inactivated
Urine containing preservatives 		Reject

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Urine Refrigerated 7 days

Useful For
Suggests clinical disorders or settings where the test may be helpful

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

The mumps virus is a single-stranded, negative-sense RNA paramyxovirus belonging to the Rubulavirus family. Symptoms of infection include painful swollen salivary glands (parotitis), fever, headache, muscle aches, weakness, and fatigue. Complications may include pancreatitis, orchitis, encephalitis, meningitis, or hearing loss. Oftentimes, mumps is diagnosed based on the characteristic swollen salivary glands. The mumps virus is spread person-to-person through contact with infected respiratory droplets or saliva. It can also be transmitted by direct contact with contaminated fomites. Laboratory diagnosis of mumps cases can be through serologic detection of mumps-specific IgM antibodies, molecular detection of mumps virus RNA, or viral culture. The use of real-time polymerase chain reaction assays can provide more rapid laboratory confirmation of mumps shortly after symptom onset compared to serologic testing and provides a shorter turnaround time than viral culture. Buccal swabs are the preferred specimen type for the detection of mumps virus, but urine may also be collected for viral detection.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Negative

Interpretation
Provides information to assist in interpretation of the test results

A positive result indicates the presence of mumps virus RNA in the specimen.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

A negative test does not rule-out infection with mumps virus. Therefore, the results should be used in conjunction with clinical findings and serologic test results to make an accurate diagnosis. The potential for false-negative results exists due to improper sample collection or viral variants.

Supportive Data

The following validation data support the use of this assay for clinical testing.

 

Accuracy:

Accuracy studies were performed by testing negative and positive (near the limit of detection) urine and buccal swab samples. Both urine and buccal swabs yielded 100% positive agreement and 100% negative agreement with expected results.


Analytical Sensitivity/Limit of Detection:

The lower limit of detection of this assay is 1.25 genome copies/mcL for urine and buccal swabs.

 

Precision:

Inter-assay and intra-assay precisions were 100%.

 

Specificity:

No sequences were identified that would result in cross-reactivity with the assay by in silico analysis. No cross-reactivity was detected in experiments testing a panel of nucleic acid extracts from more than 50 bacterial, fungal, and viral organisms causing similar disease or commonly found in urine or buccal swabs.

 

Reportable Range:

This is a qualitative assay, and the results are reported as either negative or positive for the mumps virus target.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Grennan D: Mumps. JAMA. 2019 Sep 10;322(10):1022

2. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases: Mumps For Healthcare Providers. CDC; Updated March 08, 2021. Accessed September 13, 2022. Available at www.cdc.gov/mumps/hcp.html

3. Su SB, Chang HL, Chen AKT: Current status of mumps virus infection: Epidemiology, pathogenesis, and vaccine. Int J Environ Res Public Health. 2020 Mar 5;17(5):1686

Method Description
Describes how the test is performed and provides a method-specific reference

The mumps virus laboratory-developed (LDT) real-time polymerase chain reaction (RT-PCR) assay is designed for the qualitative detect of mumps virus RNA from urine and buccal swabs of patients with suspected infection. Mumps virus RNA in clinical specimens is first extracted using the NucliSENS easyMag/EMAG (bioMerieux) instruments according to manufacturer instructions. As a component of extraction, a lysis buffer is first added to clinical specimens in a class II biosafety cabinet (BSC). At this step, any mumps virus that may be present in the sample is inactivated, rendering it non-infectious. Following the addition of lysis buffer, specimens are safe to remove from the BSC and placed onto an instrument for automated extraction. A sample input of 200 mcL will be extracted with an elution volume of 50 mcL.

 

This assay employs a reverse transcription reaction to convert RNA to complementary DNA (cDNA). Oligonucleotide forward and reverse primers specific to the matrix protein (M) gene region of the mumps virus amplify the target sequence. A TaqMan probe labeled with the fluorophore FAM and specific to the target region of mumps virus RNA bind to amplified mumps RNA virus product. Ribonuclease P (RNase P) is used as an internal control. Oligonucleotide forward and reverse primers specific to the p30 subunit of RNase P amplify the internal control target sequence. A TaqMan probe labeled with fluorophore Cy5 and specific to RNase P bind to the amplified RNase P product. The dye-labeled TaqMan probes allow for the detection of the target and internal control in the corresponding channel of the Roche LightCycler 480 II (LC480) instrument. Detection of the target M gene region indicates the presence of mumps virus RNA in the specimen. The clinical validity of RT-PCR for the detection of mumps virus RNA in urine and buccal swabs as well as the highly conserved nature of the mumps M gene target is documented in peer-reviewed literature.(Unpublished Mayo method)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Friday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

1 to 3 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

1 week

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their account representative. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

87798

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
MUMPU Mumps Virus PCR, Urine 86580-8
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
617824 Mumps Virus PCR, Urine 86580-8

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports